HEALTHMEDPAGE TODAY
'We Should Follow That Signal': What We Heard This Week
An FDA advisory committee supported RP1 (vusolimogene oderparepvec), a twice-administered treatment, following a statement by John Carrino of Weill Cornell Medicine emphasizing the importance of following observed signals in the data.
Mentioned
Related Signal
Adjacent reporting
- STAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and more
- FDA advisory panel backed Replimune's twice-rejected melanoma treatment in 10-3 vote
- STAT+: Pharmalittle: We’re reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and more
- STAT+: Pharmalittle: We’re reading about a U.S. peptide panel’s votes, Amgen scuffling with the FDA, and more